4A. Types of serological tests
A. Primary serological tests
Detect the initial binding between antigen and antibody. The reaction is not visible and needs a label/instrument.
Examples: ELISA, radioimmunoassay (RIA).
B. Secondary serological tests
Detect visible effects of antigen-antibody binding such as clumping or precipitate formation.
Examples: agglutination test, precipitation/immunodiffusion test.
C. Tertiary serological tests
Detect the biological effects produced by antigen-antibody reactions in cells or living systems.
Examples: complement fixation test, neutralization test.
4B. Agglutination vs precipitation
| Feature | Agglutination | Precipitation |
|---|
| Antigen | Particulate/insoluble, e.g. cells, bacteria, latex particles | Soluble antigen |
| Visible result | Clumping of particles | Insoluble precipitate or precipitin line/ring |
| Example | Widal test, latex RF test | Ouchterlony test, radial immunodiffusion |
4C. Principle of radial immunodiffusion (RID)
Antigen placed in a well diffuses radially into agar containing specific antibody. At the zone of equivalence, a precipitin ring forms. The square of ring diameter is proportional to antigen concentration.
Agar containing antibody
┌───────────────┐
│ ○○○○○ │ ← precipitin ring
│ ○ Ag ○ │
│ ○○○○○ │
└───────────────┘
More antigen → larger ring diameter
Medical Microbiology 9e, p. 49.
4D. Principle of immunochromatography
A liquid sample moves along a membrane by capillary action. If target antigen or antibody is present, it binds labelled reagent and is captured at the test line, producing a visible coloured line. The control line confirms that the test worked.
Sample → [Conjugate pad] → [Test line] → [Control line] → Absorbent pad
target + label test valid
Example: pregnancy test, rapid malaria antigen test, rapid COVID-19 antigen test.
4E. Ouchterlony double immunodiffusion patterns
| Drawing | Pattern | Interpretation |
|---|
text Ag1 Ag2 \ / \_____/ Ab | Identity | Ag1 and Ag2 have identical antigenic determinants. Lines fuse smoothly. |
text Ag1 Ag2 \ / \_____/ \ spur Ab | Partial identity | Antigens share some determinants, but one antigen has additional determinants. Spur points toward the simpler antigen. |
text Ag1 Ag2 \ / \ X / Ab | Non-identity | Antigens are unrelated and share no determinants. Lines cross. |
Antigen and antibody diffuse toward each other and form a visible precipitin line at equivalence. Medical Microbiology 9e, p. 49.
5A. Types of hypersensitivity reactions
| Type | Common name | Main immune component | Antigen location | Main mediators |
|---|
| I | Immediate/anaphylactic | IgE, mast cells, basophils | Soluble allergen | Histamine, leukotrienes, prostaglandins |
| II | Antibody-mediated cytotoxic | IgG or IgM | Cell surface or extracellular matrix | Complement, opsonization, ADCC |
| III | Immune-complex | IgG/IgM immune complexes | Soluble antigen complexes deposited in tissues | Complement, neutrophils |
| IV | Delayed-type/cell-mediated | T lymphocytes, macrophages | Tissue or cell-associated antigen | Cytokines, e.g. IFN-γ; cytotoxic T cells |
5B. Mechanism and examples
| Type | Underlying mechanism | Examples |
|---|
| I | Allergen cross-links IgE on mast cells, causing rapid mediator release. | Anaphylaxis; allergic rhinitis/asthma |
| II | IgG/IgM binds cells or tissue, activating complement or promoting phagocytosis/ADCC. | Mismatched blood transfusion; hemolytic disease of the newborn |
| III | Antigen-antibody complexes deposit in tissues, activate complement, and recruit neutrophils. | Serum sickness; SLE |
| IV | Sensitized T cells release cytokines or directly kill target cells; reaction occurs after 48-72 h. | Contact dermatitis; Mantoux test |
5C. Two phases of Type I hypersensitivity
- Sensitization phase: First exposure to allergen causes Th2-mediated IgE production. IgE attaches to mast cells/basophils.
- Effector phase: On re-exposure, allergen cross-links mast-cell-bound IgE, causing an immediate reaction and a late inflammatory reaction.
First exposure: Allergen → IgE production → IgE binds mast cell
Re-exposure: Allergen + IgE-coated mast cell → mediator release
5D. Mantoux test: principle and clinical importance
Principle: Intradermal PPD is injected. In a person previously sensitized to Mycobacterium tuberculosis, memory T cells cause a Type IV delayed hypersensitivity reaction, producing induration after 48-72 hours.
Clinical importance: Used to detect TB infection, especially latent TB. Measure
induration only, not redness. It cannot by itself distinguish latent from active TB.
CDC testing guidance explains that interpretation depends on risk category.
5E. Causes of false-negative PPD test
- Very recent TB infection, before immune sensitization
- Severe or overwhelming TB disease
- HIV infection or other immunosuppression
- Corticosteroids, chemotherapy, or TNF-α inhibitors
- Malnutrition
- Very young age or advanced age
- Recent live-virus vaccination
- Incorrect administration, storage, or reading of test
5F. Causes of false-positive PPD test
- Previous BCG vaccination
- Infection with non-tuberculous mycobacteria
- Incorrect measurement or interpretation
- Technical/administration error
5H. Mantoux test interpretation
| Induration | Interpretation |
|---|
| <5 mm | Usually negative |
| ≥5 mm | Positive in high-risk people: HIV, recent TB contact, transplant recipients, significant immunosuppression, or chest X-ray evidence of old TB |
| ≥10 mm | Positive in moderate-risk persons: recent immigrants from high-TB countries, healthcare/laboratory workers, people in congregate settings, diabetes, chronic kidney disease, children <5 years |
| ≥15 mm | Positive in persons with no known TB risk factors |
These thresholds are based on induration, not erythema.
CDC criteria
5I. Case: 25-year-old immigrant, previous BCG, PPD = 12 mm
Interpretation: Positive PPD, because an immigrant from a high-TB-prevalence country has a positive threshold of ≥10 mm.
Action: Refer for evaluation to exclude active TB, including symptom review and chest radiograph. An
IGRA blood test is preferred in BCG-vaccinated people because BCG can produce a false-positive PPD result. BCG history should not simply be used to dismiss this 12-mm result.
CDC BCG guidance supports using IGRA in BCG-vaccinated people.